IPO 2026
SME IPO
IPO GMP
Subscription
Allotment
Listing

Q-Line Biotech NSE SME IPO review

  • The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
  • It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
  • As the company has no listed peers, it is trying to extract fancy price for its IPO.
  • Based on its overall financial data, the issue appears fully priced.
  • Well-informed investors may park moderate funds for long term.
Dilip Davda

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges. 

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBLā€™s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipmentā€™s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipmentā€™s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipmentā€™s and devices as per the technical collaboration and specifications provided by the partners or companies. 

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Q-Line Biotech IPO

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share.  The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes. 

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM groupā€™s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 ā€“ Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, companyā€™s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr. 

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained. 

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended Revenue Expense PAT Assets
2023 ā‚¹184.81 ā‚¹154.97 ā‚¹32.10 ā‚¹251.58
2024 ā‚¹206.45 ā‚¹175.85 ā‚¹34.44 ā‚¹339.25
2025 ā‚¹322.58 ā‚¹261.43 ā‚¹28.13 ā‚¹455.49
Dec 2025 ā‚¹236.50 ā‚¹186.96 ā‚¹38.69 ā‚¹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects. 

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company Face Value (ā‚¹) EPS basic (ā‚¹)Ā  EPS Diluted (ā‚¹) RONW (%) P/E Ratio NAV (ā‚¹)
Powerica Limited 5 15.26Ā  15.26 15.37 %Ā  24.45 99.76
Listed Peers
Cummins India Limited 2 72.15Ā  72.15 26.45% 64.13Ā  272.78
Kirloskar Oil Engines Limited 2 33.71 33.60 15.85% 43.24 212.60
NTPC Green Energy Limited 10 0.67 0.67 2.58% 129.40 21.88
Acme Solar Holdings Limited 2 4.55 4.53 5.59% 50.74Ā  74.54
Adani Green Energy Limited 10 8.37 8.37 11.90%Ā  101.53Ā  76.62
Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion
Q-Line Biotech IPO FAQs
1. What is Q-Line Biotech IPO? āŒ„
Q-Line Biotech IPO is SME IPO. The company is going to raise ā‚¹214 Crores via IPO. The issue is priced at ā‚¹326 to ā‚¹343 per equity share. The IPO is to be listed on NSE SME.
2. When Q-Line Biotech IPO will open for subscription? āŒ„
The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.
3. What is Q-Line Biotech IPO Investors Portion? āŒ„
The investorsā€™ portion for QIB is 50%, NII is 15%, and Retail is 35%.
4. How to Apply the Q-Line Biotech IPO? āŒ„
You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.
5. What is Q-Line Biotech IPO Issue Size? āŒ„
Q-Line Biotech IPO issue size is ā‚¹214 crores.
6. What is Q-Line Biotech IPO Price Band? āŒ„
Q-Line Biotech IPO Price Band is ā‚¹326 to ā‚¹343.
7. What is Q-Line Biotech IPO Lot Size? āŒ„
The minimum bid is 800 Shares with ā‚¹2,74,400 amount.
8. What is the Q-Line Biotech IPO Allotment Date? āŒ„
Q-Line Biotech IPO allotment date is May 26,2026.
9. What is the Q-Line Biotech IPO Listing Date? āŒ„
Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Vegorama Punjabi Angithi IPO Review: APPLY or AVOID?

Join
Follow Us
Add Source
Follow
Vegorama Punjabi Angithi Limited is an Indian food-service company operating in the Quick Service Restaurant (QSR) and cloud kitchen segment under the ā€œPunjabi Angithiā€ brand. As we know, the food services sector is increasing day by day, and long-term investment allows people to gain; however, investment should be made with the checking of all the necessary financial statements. The IPO will be open for subscription on May 20, 2026, and close on May 22, 2026. The Vegorama Punjabi Angithi IPO price band is set between ā‚¹73 to ā‚¹77 per share. As per the RHP, the company plans to raise around ā‚¹38.38 crores through an Initial public offering (IPO).
Apply for an IPO
Vegorama Punjabi Angithi IPO
Review IPO Details GMP Messages Subscription Allotment Listing

As an investor, it can be very challenging to decide whether the Vegorama Punjabi Angithi IPO is a good or bad investment. Not anymore, as in this blog, we will provide you with all the necessary details related to the Vegorama Punjabi Angithi IPO to help you decide whether you should Apply or Not. Read on to know the IPO risks, strengths, valuation, financial details, and expert opinion to make your investment decision better. 

Vegorama Punjabi Angithi IPO Review 

ReviewerRecommendation
IPO WatchMay Apply

Strengths: 

  • Its team conducts in-depth research on locations and opens its cloud kitchens or fine dining restaurants only at prime locations with strong future growth potential.
  • The firm has established its strong presence by delivering authentic flavors, exceptional service, and a customer-focused approach.
  • Verogama Punjabi has been known to provide fresh, flavourful, high-quality, and innovative menu at affordable prices.
  • The firm has an extensive presence across social media, with 44 thousand followers on Instagram and 4.0 out of 5.0 ratings on food delivery platforms.

Weaknesses: 

  • Not being able to find the right location or city for future expansion or to open new cloud kitchens and fine dining restaurants can negatively impact the business.
  • Shutdown or slowdown of its cloud kitchens and fine dining restaurant can badly affect the business and financial health.
  • About 92% of the firmā€™s revenue comes from its top 10 customers. Any cancellation or reduction of orders from these customers can adversely impact the overall business and its operations.
  • Around 91% of the companyā€™s revenue comes through online food delivery platforms. If customers reduce or stop ordering from these delivery platforms can negatively affect the operations and profits.

Promoters & Track Records, if any 

  • Deepak Chadha, aged 43 years, is the Promoter, Chairman, and Managing Director of the Company. He holds 1,19,22,500 of Equity shares, representing 94.44% of Pre-Issue equity capital.
  • Subash Chander Chadha, aged 74 years, is the Promoter and Executive Director of the Company. He holds 6,26,250 of Equity shares, representing 4.96% of pre-Issue equity capital.
  • Teenu Chadha, aged 44 years, is the Promoter and Executive Director of the Company. He holds 1,250 equity shares, representing 0.01% of pre-Issue equity capital.

Peer Comparison with the Company

Name of the CompanyFace Value(ā‚¹)Basic EPS (ā‚¹) RONW (%)P/E RatioNAV(ā‚¹) 
Vegorama Punjabi Angithi Limited 106.51 80.39% 11.82x2,850.38    
Speciality Restaurants Limited 104.45   6.52% 23.73x68.13   
Vikram Kamats Hospitality Limited 100.48  0.01%  85.54x 28.34   

Expansion 

  • From the IPO money, ā‚¹11.90 crores would be used for the Capital Expenditure for the construction of a banquet and fine dining restaurant. 
  • ā‚¹4.20 crores will be used for the Capital Expenditure for the construction of a centralized kitchen.
  • ā‚¹4.67 crores will be used for the Capital Expenditure for rolling out a new cloud kitchen. 
  • ā‚¹1.65 crores will be utilised for the Capital Expenditure for the upgradation of the existing cloud kitchen facilities. 
  • The rest of the money would be used for the General Corporate Purposes & Issue Expenses. 

Vegorama Punjabi Angithi IPO: Should You Apply or Not?

In 2014, the firm started its business as a cloud kitchen and takeaway service provider, and in 2020, Vegorama Punjabi Angithi established itself as one of the leading companies in the cloud kitchen segment by offering high-quality, flavourful, and affordable vegetarian North Indian cuisines. As of now, the firm operates 27 cloud kitchens located across Noida, Uttar Pradesh, Dwarka, and Delhi NCR. 

Financially, from FY23 to FY25, we saw an increase in profit by 77%, while assest, net worth, and reserves also grew in the same year.

My verdict: It’s common to see the changes in every sector at its time. Selecting a proper IPO for long-term investment. An IPO investment should be done after proper financial and business analysis. Some IPOs may be suitable for long-term investment if the company has strong fundamentals. Vegorama Punjabi Angithi IPO might be considered for moderate and long-term investment, along with deep research and checking all the necessary financial concepts. 

Apart from financial statements, investors also check the IPO GMP for the estimated listing price. However, the grey market premium is unofficial; one should not only rely on it, but rather focus on the companyā€™s history and financials. 

Please note:   

Investors are advised to make their own decisions and apply entirely at their own risk. This article is written using information from the companyā€™s RHP (Red Herring Prospectus) data and online sources. If you have any queries, kindly contact the IPO Watch Team. 

Table of Contents

Picture of Jagat Joshi

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.
Picture of Jagat Joshi

Jagat Joshi

Add IPOWatch to your Google News feed.   google news button

Leave a Reply

Your email address will not be published. Required fields are marked *

Current Mainboard IPO

Current SME IPO

Latest IPO News

IMP LINKS

Related Posts

Apply IPO